Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicotinamide adenine dinucleotide (NAD) is a coenzyme found in all living cells. It exists in two forms, the oxidized form (NAD+) and the reduced form (NADH). NAD+ plays a central role in cellular metabolism by acting as an electron carrier in redox reactions, particularly within glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation. Beyond its metabolic functions, NAD+ serves as a substrate for enzymes involved in DNA repair (such as poly(ADP-ribose) polymerases), protein deacetylation (sirtuins), and cell signaling pathways including ADP-ribosylation. It is synthesized via de novo pathways from amino acids or through salvage pathways recycling precursors like nicotinamide. In mammals, most tissues rely on salvage synthesis to maintain adequate levels of this essential molecule[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotinamide adenine dinucleotide.